A Phase 3, Randomized Double-Blind Study of the Efficacy and Safety of Low-Dose SHP465 Mixed Amphetamine Salts Extended-Release in Children with Attention-Deficit/Hyperactivity Disorder
Greg Mattingly, Valerie Arnold, Brian Yan, Ming Yu, Brigitte Robertson, Greg Mattingly, Valerie Arnold, Brian Yan, Ming Yu, Brigitte Robertson
Abstract
Objectives: In a previous pivotal study of children and adolescents (aged 6-17 years) with attention-deficit/hyperactivity disorder (ADHD), dose-optimized SHP465 mixed amphetamine salts (MAS) extended-release (12.5-25 mg once daily) was superior to placebo in reducing ADHD symptoms. This study evaluated the efficacy, tolerability, and safety of 6.25 mg SHP465 MAS once daily (one-half the lowest approved dose for adolescents and adults) versus placebo in children aged 6-12 years with ADHD. Methods: Children (aged 6-12 years) with Diagnostic and Statistical Manual of Mental Disorders, Fifth edition-defined ADHD; baseline ADHD-Rating Scale, Fifth Edition, Child, Home Version total scores (ADHD-RS-5-HV-TS) ≥28; and baseline Clinical Global Impressions-Severity scores ≥4 were eligible. Participants received 6.25 mg SHP465 MAS once daily or placebo for 4 weeks. The primary (ADHD-RS-5-HV-TS change from baseline at week 4) and key secondary (Clinical Global Impressions-Improvement [CGI-I] score at week 4) efficacy end points were assessed using linear mixed-effects models for repeated measures. Safety and tolerability assessments included treatment-emergent adverse events (TEAEs) and vital sign changes. Results: Of 89 randomized participants, 83 completed the study (placebo, n = 41; SHP465 MAS, n = 42). At week 4, the least squares mean (95% confidence interval) treatment differences (SHP465 MAS-placebo) were not statistically significant for ADHD-RS-5-HV-TS change (-1.9 [-6.8 to 3.1], p = 0.451; effect size [ES] = 0.17) or CGI-I score (-0.1 [-0.5 to 0.3], nominal p = 0.597; ES = 0.12). The percentage of participants reporting TEAEs was 16.3% with placebo and 24.4% with SHP465 MAS. The most frequently reported TEAEs (placebo; SHP465 MAS) were headache (7.0%; 4.4%) and decreased appetite (4.7%; 2.2%). Minimal increases in blood pressure were observed with SHP465 MAS at the final on-treatment assessment. Conclusions: SHP465 MAS 6.25 mg once daily (one-half the lowest dose approved for adolescents and adults) was well tolerated in children aged 6-12 years but was not superior to placebo in reducing ADHD symptoms, suggesting that this dose of SHP465 MAS was subtherapeutic in this age group. The Clinical Trial Registration number: NCT03325881.
Keywords: SHP465 (Mydayis) mixed amphetamine salts; attention-deficit/hyperactivity disorder (ADHD); children; efficacy; safety and tolerability.
Figures
References
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Washington, DC: American Psychiatric Association; 2013
- Biederman J, Krishnan S, Zhang Y, McGough JJ, Findling RL: Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: A phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. Clin Ther 29:450–463, 2007
- Biederman J, Lopez FA, Boellner SW, Chandler MC: A randomized, double-blind, placebo-controlled, parallel-group study of SLI381 (Adderall XR) in children with attention-deficit/hyperactivity disorder. Pediatrics 110:258–266, 2002
- Brams M, Childress AC, Greenbaum M, Yu M, Yan B, Jaffee M, Robertson B: SHP465 mixed amphetamine salts in the treatment of attention-deficit/hyperactivity disorder in children and adolescents: Results of a randomized, double-blind placebo-controlled study. J Child Adolesc Psychopharmacol 28:19–28, 2018
- Canafax DM, Bhanegaonkar A, Bharmal M, Calloway M: Validation of the post sleep questionnaire for assessing subjects with restless legs syndrome: Results from two double-blind, multicenter, placebo-controlled clinical trials. BMC Neurol 11:48, 2011
- DuPaul GJ, Power TJ, Anastopoulos AD, Reid R: Introduction to the ADHD rating scales In: ADHD Rating Scale-5 for Children and Adolescents: Checklists, Norms, and Clinical Interpretation. New York, Guilford Publications, 2016, pp. 1–6
- Ermer JC, Shojaei A, Pennick M, Anderson CS, Silverberg A, Youcha SH: Bioavailability of triple-bead mixed amphetamine salts compared with a dose-augmentation strategy of mixed amphetamine salts extended release plus mixed amphetamine salts immediate release. Curr Med Res Opin 23:1067–1075, 2007
- Findling RL, Childress AC, Cutler AJ, Gasior M, Hamdani M, Ferreira-Cornwell MC, Squires L: Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 50:395–405, 2011
- Frick G, Yan B, Adler LA: Triple-bead mixed amphetamine salts (SHP465) in adults with ADHD: Results of a phase 3, double-blind, randomized, forced-dose trial. J Atten Disord 24:402–413, 2020
- Guy W: Clinical Global Impressions. Rockville (Maryland), US Department of Health, Education, and Welfare; Public Health Service; Alcohol, Drug Abuse and Mental Health Administration, NIMH Psychopharmacology Research Branch, 1976
- McCracken JT, Biederman J, Greenhill LL, Swanson JM, McGough JJ, Spencer TJ, Posner K, Wigal S, Pataki C, Zhang Y, Tulloch S: Analog classroom assessment of a once-daily mixed amphetamine formulation, SLI381 (Adderall XR), in children with ADHD. J Am Acad Child Adolesc Psychiatry 42:673–683, 2003
- Mydayis® (Mixed Salts of a Single-Entity Amphetamine Product): Full Prescribing Information. Lexington (Massachusetts), Shire US, Inc., 2019
- Owens JA, Spirito A, McGuinn M: The Children's Sleep Habits Questionnaire (CSHQ): Psychometric properties of a survey instrument for school-aged children. Sleep 23:1043–1051, 2000
- Pliszka SR, Browne RG, Olvera RL, Wynne SK: A double-blind, placebo-controlled study of Adderall and methylphenidate in the treatment of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 39:619–626, 2000
- Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, Currier GW, Melvin GA, Greenhill L, Shen S, Mann JJ: The Columbia-Suicide Severity Rating Scale: Initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry 168:1266–1277, 2011
- Spencer TJ, Adler LA, Weisler RH, Youcha SH: Triple-bead mixed amphetamine salts (SPD465), a novel, enhanced extended-release amphetamine formulation for the treatment of adults with ADHD: A randomized, double-blind, multicenter, placebo-controlled study. J Clin Psychiatry 69:1437–1448, 2008
- Spencer TJ, Wilens TE, Biederman J, Weisler RH, Read SC, Pratt R: Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: A 4-week, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 28:266–279, 2006
- Stein MA, Waldman ID, Charney E, Aryal S, Sable C, Gruber R, Newcorn JH: Dose effects and comparative effectiveness of extended release dexmethylphenidate and mixed amphetamine salts. J Child Adolesc Psychopharmacol 21:581–588, 2011
- Swanson J, Wigal S, Greenhill L, Browne R, Waslick B, Lerner M, Williams L, Flynn D, Agler D, Crowley KL, Fineberg E, Regino R, Baren M, Cantwell D: Objective and subjective measures of the pharmacodynamic effects of Adderall in the treatment of children with ADHD in a controlled laboratory classroom setting. Psychopharmacol Bull 34:55–60, 1998
- United States Food and Drug Administration: Guidance for industry: How to comply with the Pediatric Research Equity Act. US Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Available at: (accessed March29, 2019)
- Weisler RH, Greenbaum M, Arnold V, Yu M, Yan B, Jaffee M, Robertson B: Efficacy and safety of SHP465 mixed amphetamine salts in the treatment of attention-deficit/hyperactivity disorder in adults: Results of a randomized, double-blind, placebo-controlled, forced-dose clinical study. CNS Drugs 31:685–697, 2017
- Wigal S, Lopez F, Frick G, Yan B, Robertson B, Madhoo M: A randomized, double-blind, 3-way crossover, analog classroom study of SHP465 mixed amphetamine salts extended-release in adolescents with ADHD. Postgrad Med 131:212–224, 2019
- Wigal T, Brams M, Frick G, Yan B, Madhoo M: A randomized, double-blind study of SHP465 mixed amphetamine salts extended-release in adults with ADHD using a simulated adult workplace design. Postgrad Med 130:481–493, 2018a
- Wigal T, Childress A, Frick G, Yan B, Wigal S, Madhoo M: Effects of SHP465 mixed amphetamine salts in adults with ADHD in a simulated adult workplace environment. Postgrad Med 130:111–121, 2018b
Source: PubMed